Dan joined Mirati in 2020 as Chief Operating Officer. Dan brings 20 years of biopharma industry experience to his role in leading the company’s corporate strategy, program and alliance management, finance, business development, legal and compliance, and corporate affairs functions.
Dan joined Mirati from Spark Therapeutics (acquired by Roche), where he served as Chief Business Officer, a position he held since 2016. At Spark, Dan was responsible for the Corporate Strategy and Public Affairs organization, including leadership of Spark’s corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset and program management, and corporate communications functions.
Prior to joining Spark, Dan was a Managing Director at Centerview Partners, where he served from 2009-2016 as a founding member of the firm’s healthcare advisory practice. He has extensive experience in corporate strategy, mergers and acquisitions, partnerships and investor relations. He also has advised on over $50 billion in biopharma transactions.
Dan’s experience also includes healthcare investment banking with Merrill Lynch and management consulting in the life sciences practice at PRTM.
Dan earned his MBA in Healthcare Management from The Wharton School of the University of Pennsylvania, and his B.S. in engineering from Cornell University.